Format
Sort by

Send to

Choose Destination

Search results

Items: 2

1.

Neutralization of prolactin receptor function by monoclonal antibody LFA102, a novel potential therapeutic for the treatment of breast cancer.

Damiano JS, Rendahl KG, Karim C, Embry MG, Ghoddusi M, Holash J, Fanidi A, Abrams TJ, Abraham JA.

Mol Cancer Ther. 2013 Mar;12(3):295-305. doi: 10.1158/1535-7163.MCT-12-0886. Epub 2012 Dec 27.

2.

CHIR-258 is efficacious in a newly developed fibroblast growth factor receptor 3-expressing orthotopic multiple myeloma model in mice.

Xin X, Abrams TJ, Hollenbach PW, Rendahl KG, Tang Y, Oei YA, Embry MG, Swinarski DE, Garrett EN, Pryer NK, Trudel S, Jallal B, Mendel DB, Heise CC.

Clin Cancer Res. 2006 Aug 15;12(16):4908-15.

Supplemental Content

Loading ...
Support Center